PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons as required to response a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

as mami chaote as nacassari)

Complete if Known 10/771,440 Application Number February 5, 2004 Filing Date First Named Inventor Michal DANIELY et al A -- I I-- : 4 16/13

(use as many sheets as necessary)					Art Unit		1643	1643		
					Examin	Examiner Name DUF		IFFY, BRADLEY		
Sheet 1		of	7	Attorney Docket Number		26003				
			U.S. PA	TENT	DOCUM	ENTS				
Examiner Initials*	Cite No.	Document Number	Publication DD-MMM-1	Date				Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number-Kind Code ^{2 (if known)}			Henning et al.			· · · · · · · · · · · · · · · · · · ·		
	1	US-2002/0106685	08-Aug-200							
	2 US-2002/0127542 1		12-Sep-2002		Beug et al.					

							-		_	

									_	
					ļ					
									_	
			FOREIGN	PATE	 NT DOCI	UMENTS				
Examiner	Cite					Name of Patentee		Pages, Columns, Lines,	Γ	
Initials*	No. 1	Foreign Patent Documents Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			ation Date Name of Patentee or MM-YYYY Applicant of Cited Document			Where Relevant Passages or Relevant Figures Appear	6	
	3	PCT WO 03/040064		15-May-2003		Daniely et al.				
				-					<u> </u>	
				 					├	
				-				-	├	
									⊢	
				 					┢	
				 					T	
					· · · · · ·	-				
									L	
									_	

Date Considered

Examiner

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Complete if Known Substitute for form 1449A/PTO 10/771,440 Application Number Filing Date February 5, 2004 INFORMATION DISCLOSURE First Named Inventor **DANIELY** Michal et al STATEMENT BY APPLICANT Group Art Unit 1643 **DUFFY, BRADLEY** Examiner Name (use as many sheets as necessary) 7 Attorney Docket Number Sheet 26003 OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T^2 Initials No.1 publisher, city and/or country where published. Bielorai et al. "Combined Analysis of Morphology and FISH in Follow-Up of 4 Minimal Residual Disease (MRD) in A Child With Ph+ Acute Lymphoblastic Leukemia (ALL)", Cancer Genetics and Cytogenetics, 138: 64-68, 2002. Abstract. 5 Bielorai et al. "Combined Analysis of Morphology and Fluorescence In Situ Hybridization in Follow-Up of Minimal Residual Disease in A Child With Philadelphia-Positive Acute Lymphoblastic Leukemia", Cancer Genetics and Cytogenetics, 138(1): 64-68, 2002. P.65, r-h Col., § 1, P.67, l-h Col., § 2. Bielorai et al. "Follow-Up of Minimal Residual Disease (MRD) in A Child With 6 Ph+ Acute Lymphoblastic Leukemia (ALL) Using Mutiparametric Cell Scanning System", 43th ASH Annual Meeting, Blood, 98(Part 20: 185b, Abstract #4433, 2001. Abstract. 7 Bielorai et al. "Full Hematopoietic Engraftment After Allogeneic Peripheral Blood Stem Cell Transplantation Without Conditioning in SCID Patients", 44th ASH Annual Meeting, Blood, 100(Part 1): 409, 2002. Bielorai et al. "Multilineage Hematopoietic Engraftment After Allogeneic 8 Peripheral Blood Stem Cell Transplantation Without Conditioning in SCID Patients", Bone Marrow Transplantation, P.1-4, 2004. Bielorai et al. "Multilineage Hematopoietic Engraftment in SCID Patients 9 Transplanted With Allogeneic Peripheral Blood Stem Cells Without Preparative Regimen", 29th Annual Meeting of the European Group for Blood and Marrow Transplantation, Istanbul, Turkey, 2003. Abstract. Chen et al. "Targeting of Abnormal Plasma Cells With Image Analysis May 10 Significantly Improve the Abnormal Detection Rate Determined by FISH in Multiple Myeloma", 2004 Annual Meeting of the United states and Canadian Academy of Pathology, Vancouver, Canada, Abstract #1487, 2004. Abstract. Daniely et al. "Combined Analysis of Morphology and FISH for the Monitoring of 11 Bladder Cancer", Annales de Genetique, 46(2-3): 153, 2003. & Fourth European Cytogenetics Conference, Bologna, Italy, 2003. Daniely et al. "Combined Analysis of Morphology and Fluorescence in Situ 12 Hybridization Significantly Increases Accuracy of Bladder Cancer Detection in Voided Urine Samples", Urology, 66: 1354-1359, 2005. Debes-Marun et al. "Circulating B Lymphocytes From Patients With Multiple 13 Myeloma Harbour T(4;14) Translocations and Chromosome 13 Deletions. Session Type: Oral Session", Blood, 106(11): Abstract #500, 2005.

Date

Considered

Examiner

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Complete if Known Substitute for form 1449A/PTO Application Number 10/771,440 Filing Date 05-Feb-2004 INFORMATION DISCLOSURE First Named Inventor DANIELY Michal et al STATEMENT BY APPLICANT Art Unit 1643 Examiner Name **DUFFY, BRADLEY** · (use as many sheets as necessary) Attorney Docket Number 7 Sheet OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Initials* item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T² publisher, city and/or country where published. 14 Hardan et al. "Detection of 13g Deletion in the Bone Marrow Cells of Patients With Multiple Myeloma Using Combined Morphological and FISH Analysis", Blood, 100(11): 392a, Abstract# 1522, 2002. & 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, USA, 2002. 15 Hardan et al. "Determination of Chromosome 13 Status in Bone Marrow Cells of Patients With Multiple Myeloma Using Combined Morphologic and Fluorescence In Situ Hybridization Analysis", Experimental Hematology, 32: 254-260, 2004. 16 Inoue et al. "Chromosomal Numerical Aberrations of Exfoliated Cells in the Urine Detected by Fluorescence In Situ Hybridization: Clinical Implication for the Detection of Bladder Cancer", Urological Research, 28(1): 57-61, 2000. P.58, § 1, Fig. 1, Table 2. Kaplinsky et al. "Combined Analysis of Morphology and FISH Using the Duet™ 17 Automatic Cells Scanning System, Increases the Accuracy of Leukemia Diagnosis", The Hematology Journal, 3: 201, Poster No.0668, 2002. Abstract. 18 Kaplinsky et al. "Haemopoietic Growth Factor. Tetraploid Myeloid Cells in Donors of Peripheral Blood Stem Cells Treated With RhG-CSF", Bone Marrow Transplantation, 32: 31-34, 2003. Kaplinsky et al. "Increased Accuracy of Leukemia Diagnosis by Combined 19 Analysis of Morphology and FISH Using the Duet™ Automatic Cell Scanning System", European Journal of Human Genetics, 10(Suppl.1): 90, 2002. & European Human Genetics Conference 2002 in Conjunction With the European Meeting on Psychological ASP, Strasbourg, France, 2002. 20 Kaplinsky et al. "Minimal Residual Disease and Chimerism Detection After Bone-Marrow Transplantation Using An Automatic Cell Scanning System", 43rd ASH Annual Meeting, Blood, 98(Part 2): 348b, 2001. Abstract. 21 Kneller et al. "Acquisition of Ph-Chromosome With Minor BCR/ABL Fusion as Second Clonal Event Following T-MDS With Chromosome 7 Abnormalities in A Patient Treated for Hodgkin Disease", Cancer Genetic and Cytogenetic, 199: 58-62, 2005. 22 Knudson et al. "Comparison of the BioView Duet Automated Dot Counting System to Technologist Scoring Using the D-FISH Strategy in Patients With CML", Association of Genetic Technology, Atlanta, GA, USA. Abstract. Examiner Date

Considered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1993, no persons are required				Complete if Known					
	Sut	ostitute for form 1449A/PT	0		Application Number 10/771,440				
TAIT	SODA (ATION DICC	LOCID	DE	Filing Date	05-Feb-2004			
		ATION DISC			First Named Inventor	DANIELY Micha	ıl et al		
ST	ATEM:	ENT BY APP	LICA	NT	Art Unit	1643			
(use as many sheets as necessary)					Examiner Name	DUFFY, BRADLEY			
Sheet	1	4	Of	7	Attorney Docket Number	26003			
	1	OTHER PRIOR	ART –	NON PATE	NT LITERATURE DOCUM	MENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
_	23	Lev et al. "Automatic Scanning of Interphase FISH for Prenatal Diagnosis in Uncultured Amniocytes", Genetic Testing, 9(1): 41-47, 2005.							
	24	Malinger et al. "Automatic Scanning of Interphase FISH for Prenatal Diagnosis in Uncultured Amniocytes", Annales de Génétiques, International Journal of Human and Medical Genetics, 46(13.27): 323, 2003. Abstract.							
	25	McCormick et al. "HER2 Assessment By Immunohistochemical Analysis and Fluorescence In Situ Hybridization", American Journal of Clinical Pathology, 117: 935-943, 2002. See Abstract.							
	26	Raanani et al. "Philadelphia-Chromosome-Positive T-Lymphoblastic Leukemia: Acute Leukemia or Chronic Myelogenous Leukemia Blastic Crisis", Acta Haematologica, 113: 181-189, 2005.							
	27	Rosenberg et al. "Major Mutations in Calf-1 and Calf-2 Domains of Glycoprotein IIb in Patients With Glanzmann Thrombasthenia Enable GPIIb/IIIa Complex Formation, But Impair Its Transport From the Endoplasmic Reticulum to the Golgi Apparatus", Blood, 101(12): 4808- 4816, 2003.							
	28	Rothman et al. "A New AML1 Deletion in Pediatric TEL/AML1 Positive ALL Patients: Detection and Monitoring of Minimal Residual Disease by FISH Analysis", 38th Annual Congress of the Israeli Society for Clinical Laboratory Sciences, Tel Aviv, IL, 2004. Abstract.							
	29	Rothman et al. " Leukemia Patien Breakpoint (Intro de Génétiques, I 139, 2003. Abstr	Additionants With Ton 2) and nternationact.	al Cytogeneti (12:12): Del Subsequent nal Journal of	c Events in Pediatric Acute L etion of the Region 3' to the A Deletion of the Normal TEL f Human and Medical Genetic	AML1 Allele", Annales cs, 46(2.68):			
	30	Rothman et al. "Co-Existence of Multiple Subclones in TEL-AML1 at Diagnosis of Acute Lymphoblastic Leukaemia in Association With Submicroscopic Deletion of AML1", British Journal of Haematology, 129: 491-498, 2005.							
	31	Cytogenetic Ana	ilysis of N r Allogen	Ainimal Resi eic Bone Ma	ical Immunophenotypic and lidual Disease in Acute Leuker rrow Transplantation", ILMA stract.	nias for Testing			

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Date Considered

Examiner

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Complete if Known Substitute for form 1449A/PTO Application Number 10/771,440 05-Feb-2004 Filing Date INFORMATION DISCLOSURE DANIELY Michal et al First Named Inventor STATEMENT BY APPLICANT Art Unit 1643 Examiner Name DUFFY, BRADLEY (use as many sheets as necessary) Attorney Docket Number 7 Sheet OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Initials* item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. T² Rothman et al. "Detection of 13q Deletion in the Bone Marrow Cells of Patients 32 With Multiple Myeloma Using Combined Morphological and FISH Analysis", The Annual Meeting of the Genetics Society of Israel, Challenges in Genetics in the 21st Century, Tel Aviv, IL, Poster P5, 2003. Abstract. Rothman et al. "Improved Detection of Chromosome 13 Status in Multiple 33 Myeloma Patients With Modern Technologies: Combined Morphological and FISH Analysis", ILMAR Conference, Tel Aviv, IL, Oral Presentation, 2003. abstract. 34 Shimoni et al. "Chimerism Detection After Bone-Marrow Transplantation, Using Combined Morphological and Cytogenetical Analysis", The Hematology Journal. 3: 201, Poster 0669, 2002. Abstract. 35 Shimoni et al. "Chimerism Testing and Detection of Minimal Residual Disease in A Patient With Ph+ Acute Lymphoblastic Leukemia After Bone Marrow Transplantation Using Multiparametric Cell Scanning System", BioView Ltd. Israel. Abstract. Shimoni et al. "Detection of host Blasts But Not Mature Hematopoietic Cells 36 Among Minute Host Populations Remaining after Allogeneic Transplantation, Using Combined Morphological and Cytogenetic Analysis, Predicts Imminent Relapse", 44th ASH Annual Meeting, Blood, 100(16/Part 2): 631a, Abstract #2485, 2002. Abstract. Slovak et al. "Fluorescence In Situ Hybridization (FISH) Targeting Plasma Cells 37 Improves the Detection of Multiple Myeloma: Phenotype/Genotype Correlation in Residual Disease Detection", The American Society of Human Genetic Society Conference, Toronto, Canada, Abstract #239, 2004. Abstract. 38 Slovak et al. "Targeting Plasma Cells Improves Detection of Cytogenetic Aberrations in Multiple Myeloma: Phenotype/Genotype Fluorescence in Situ Hybridization", Cancer Genetics and Cytogenetics, 158: 99-109, 2005. Strassburger et al. "Computerized Cell Scanning in the Classification of Testicular 39 Germ Cells in Non-Obstructive Azoospermic Patients", Annual Meeting of the Israel Society of Fertility, Tel Aviv, IL, Abstract #25, 2005. Abstract. Strassburger et al. "Morphology and Fluorescence In Situ Hybridization on the 40 Same Sperm Cell Controlled by Computerised Cell Scanning System", 19th Annual Meeting of the European Society of Human Reproduction and Embryology, Madrid, ESHRE 2003, 2003. Abstract.

Date

Considered

Examiner Signature

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Complete if Known Substitute for form 1449A/PTO Application Number 10/771,440 05-Feb-2004 Filing Date INFORMATION DISCLOSURE **DANIELY Michal et al** First Named Inventor STATEMENT BY APPLICANT Art Unit 1643 DUFFY, BRADLEY Examiner Name (use as many sheets as necessary) 7 Attorney Docket Number Sheet OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Cite Examiner Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Initials* No. item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T² publisher, city and/or country where published. 41 Strassburger et al. "Morphology Assessment and Fluorescence In-Situ Hybridization of the Same Spermatozoon Using a Computerized Cell-Scanning System", Human Reproduction, 22(1): 201-209, 2007. 42 Sulcova et al. "Computer-Assisted Fluorescence In Situ Hybridization (FISH) Analysis for Bladder Cancer Recurrence", 30th Annual Meeting of American Association of Genetic Technologists, Kansas City, Missouri, USA, Abstract #47, 2005. Abstract. 43 Trakhtenbrot et al. "Clinical Significance of the Combined Morphological, Immunophenotypic and Molecular Cytogenetic Analysis of Hematological Malignancies", Annales de Génétique, International Journal of Human and Medical Genetics, 46(2.80): 145, 2003. Abstract. Trakhtenbrot et al. "Combined Morphological and Fish Analysis of Aneuploidy in 44 Oral Premalignancy", 10th European Workshop of Molecular Cytogenetics in Human Solid Tumours, La Grande Motte, France, P.31, 2006. Abstract. 45 Trakhtenbrot et al. "Combined Morphological, Immunophenotypic and Molecular Cytogenetic Analysis of Minimal Residual Disease in Acute Leukemias for Testing Chimerism After Allogeneic Bone Marrow Transplantation", The 37th Annual Meeting of the Genetic Society of Israel Aviv, IL, Poster P6, 2003. Abstract., Tel 46 Trakhtenbrot et al. "Detection of the Full Hematopoietic Engraftment After Allogeneic Peripheral Stem Cell Transplantation Without Conditioning in SCID Patients Using Combined Morphology, Immunophenotype and Fluorescence In Situ Hybridization (FISH)", 38th Annual Congress of the Israeli Society for Clinical Laboratory Sciences, Tel Aviv, IL, 2004. Abstract. Trakhtenbrot et al. "The Multiparametric Scanning System for Evaluation of 47 Minimal Residual Disease in Hematological Malignancies", Acta Haematologica, 112: 24-29, 2004. 48 Van Agthovan et al. Differential Expression Of Estrogen, Progesterone, And Epidermal Growth Factor Receptors In Normal, Benign, And Dual Staining Immunohistochemistry", Amereican Journal of Pathology, 144(6): 1238-1246, 49 Vasir et al. "Dendritic Cell Chimersim and Function Following Nonmyeloablative Allogeneic Stem Cell Transplantation", 45th ASH Annual Meeting, Blood,

Date

Considered

Examiner

Signature

102(11/Part 1): 695a, Abstract. #2575, 2003. Abstract.

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

	Under the Pa	perwork Reduction	Act of 1995, no per	rsons are required t	o respond to a collection of information ur		MB control number.		
Substitute for form 1449A/PTO					Complete if Known				
	Sub	SHURE FOR TORM 144	YWF IU		Application Number	10/771,440			
INFORMATION DISCLOSURE					Filing Date	05-Feb-2004			
					First Named Inventor	DANIELY Michal et al			
STATEMENT BY APPLICANT			Art Unit	1643					
(use as many sheets as necessary)				Examiner Name	DUFFY, BRADLEY				
Sheet		7	Of	7	Attorney Docket Number	26003			
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS									
Examiner	Cite				ERS), title of the article (when appre				
Initials*	No. ¹	item (book, m			um, catalog, etc.) date, page(s), volume-issue number(s), d/or country where published.				
	50	Wang et al. "Computer-Assisted Fluorescance In Situ Hybridization (FISH)							
					es: Experience With 900 Case				
		Meeting of American Association of Genetic Technologists, Kansas City, Missouri, USA, 2005							
	51	Wilkinson e	t al. "Cloning	of the T(1;5)	(Q23;Q33) in A Myeloprolife	erative Disorder			
	Associated With Eosinophilia: Involvement of PDGFRB and Response to								
		Imatinib", Blood, 102(12): 4187-4190, 2003.							
	52	Wu et al. "Molecular Assessment of Erythroid Lineage Chimerism Following							
		Nonmyeloablative Allogeneic Stem Cell Transplantation", Experimental							
			, 31: 924-933,						
		110111111111111111111111111111111111111	,	,					
		•							
•									
			-						
					-		,		
							-		
	1								

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450